1 / 8

COVID-2019: Status of Favipiravir in the world

Favipiravir is also known as T-705, which is a new type of RNA polymerase inhibitor, was approved in Japan in March 2014 as another weapon for antiviral therapy for influenza A and B. Studies have shown that, in addition to influenza viruses, favipiravir may also exhibit good antiviral effects on a variety of RNA viruses, such as Ebola virus, sand virus, bunya virus, rabies virus, etc. The new coronavirus belongs to the coronavirus, is a positive chain single-stranded RNA virus with a coat membrane, and from the mechanism, favipiravir also has potential antiviral effects on the new coronavirus.<br><br>https://www.apicdmo.com/our-products/favipiravir/

apicdmo
Télécharger la présentation

COVID-2019: Status of Favipiravir in the world

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. https://www.apicdmo.com/product/259793-96-9/ APICDMO--Favipiravir CAS:259793-96-9 www.apicodmo.com

  2. What Is Favipiravir? Favipiravir is also known as T-705, which is a new type of RNA polymerase inhibitor, was approved in Japan in March 2014 as another weapon for antiviral therapy for influenza A and B. Studies have shown that, in addition to influenza viruses, favipiravir may also exhibit good antiviral effects on a variety of RNA viruses, such as Ebola virus, sand virus, bunya virus, rabies virus, etc. The new coronavirus belongs to the coronavirus, is a positive chain single-stranded RNA virus with a coat membrane, and from the mechanism, favipiravir also has potential antiviral effects on the new coronavirus. https://www.apicdmo.com/our-products/favipiravir/

  3. COVID-2019: Status of Favipiravir in the world China 1. Russia 2. India 3. More countries 4. https://www.apicdmo.com/our-products/favipiravir/

  4. China says: “Antiviral favipiravir effective against COVID-19” Randomized trials of the broad-spectrum antiviral favipiravir, marketed as an anti-influenza treatment, have shown "obvious efficacy" against COVID-19, according to Zhang Xinmin, head of the China National Center for Biotechnology Development. Zhang's comments were reported by Xinhua News Agency, China's official state-run press agency. In one trial, testing favipiravir with interferon in Shenzhen, results showed that patients treated with the combination had significantly reduced the duration of symptoms, as measured by viral load chest imaging, vs. a control group. In another study, clinical recovery rates were higher for COVID-19 patients treated with favipiravir vs. those in a control group. https://www.apicdmo.com/our-products/favipiravir/

  5. Russia says: “Favipiravir(Avifavir) has been approved to treat COVID-2019” Russia has approved an anti-influenza drug, Favipiravir, to treat Covid-19 and will start delivering it to hospitals this month, according to Russia’s sovereign wealth fund. Preliminary trials appeared to show that it could shorten recovery times for patients with Covid-19. The final stage of Favipiravir clinical trials involving 330 patients are ongoing, RDIF and ChemRar said Monday, but patients are ongoing, RDIF and ChemRar said Monday, but Russia’s Ministry of Health on Saturday already temporarily approved the use of the drug as a coronavirus treatment. favipiravir is Russia’s first Covid-19 drug and has shown high efficacy in treating patients with coronavirus during clinical trials. favipiravir has received a registration certificate from the Ministry of Health of the Russian Federation. Thus, favipiravir has become the first Favipiravir-based drug in the world approved for the treatment of Covid-19,” they said in the statement. https://www.apicdmo.com/our-products/favipiravir/

  6. India says: "Glenmark Pharmaceuticals has gained an approval from India’s drug regulator for the antiviral drug favipiravir. Glenmark Pharmaceuticals has gained an approval from India’s drug regulator for the antiviral drug favipiravir for the treatment of mild-to-moderate COVID-19 patients.Glenmark is now set to manufacture and market its favipiravir product under the brand name FabiFlu in India, and is the first oral favipiravir-approved medication in the country for the treatment of COVID-19. The approval is based on clinical evidence of favipiravir demonstrating promising results in patients with mild-to-moderate COVID-19 disease. According to Glenmark, the drug offers rapid reduction in viral load with four days and provides faster symptomatic and radiological improvement. In addition, favipiravir demonstrated clinical improvement of up to 88% among those with a mild-to-moderate case of COVID-19.“FabiFlu has demonstrated an encouraging response in mild-to-moderate COVID-19 patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications,” said Saldanha. Glenmark has also announced its intention to conduct another clinical trial to evaluate the efficacy of favipiravir and another antiviral drug, umifenovir, as a combination therapy in moderate, hospitalised adult COVID-19 patients in India. https://www.apicdmo.com/our-products/favipiravir/

  7. Attitudes from more countries on against COVID-2019 by Favipiravir The US Department of Defense developed favipiravir in partnership with MediVector, Inc. as a broad-spectrum antiviral and sponsored it through FDA Phase II and Phase III clinical trials, where it demonstrated safety in humans and efficacy against the influenza virus.Despite demonstrating safety in more than 2,000 patients and showing accelerated clearance of influenza virus by 6 to 14 hours in the Phase III trials, favipiravir remains unapproved in the UK and the USA. The Italian Pharmaceuticals Agency AIFA has approved testing antiviral drug favipiravir for the coronavirus, Health Minister Roberto Speranza said on Monday. The technical-scientific committee is developing a testing and research programme to assess the impact of the drug in the initial phases of the disease after an initial analysis of the available data on favipiravir. https://www.apicdmo.com/our-products/favipiravir/

  8. Welcome to order Favipiravir API From APICDMO!!! Email：emily@apicdmo.com Tel: +86（1368）2461609 Website: www.apicdmo.com Address: No.27-2 Keyuan Street, Economic Development District,Shanghe County, Jinan City, Shandong Province https://www.apicdmo.com/product/259793-96-9/ https://www.apicdmo.com/product/259793-88-9/ https://www.apicdmo.com/product/356783-16-9/ https://www.apicdmo.com/our-products/favipiravir/

More Related